MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Sells 130,073 Shares of IQVIA Holdings Inc. (NYSE:IQV)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 99.5% in the 4th quarter, HoldingsChannel reports. The firm owned 588 shares of the medical research company’s stock after selling 130,073 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in IQVIA were worth $116,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. FMR LLC boosted its stake in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $147,683,000. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its position in shares of IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock valued at $56,783,000 after acquiring an additional 198,808 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, Truist Financial decreased their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Stock Performance

IQV stock opened at $204.54 on Friday. The firm has a market cap of $37.12 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.14 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The business’s fifty day simple moving average is $199.47 and its two-hundred day simple moving average is $221.09.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.